Last Updated: November 16, 2026

Details for Patent: 9,220,707

« Back to Dashboard


Which drugs does patent 9,220,707 protect, and when does it expire?

Patent 9,220,707 protects SOFDRA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-one countries.

Summary for Patent: 9,220,707
Title:Method of dosing and use of soft anticholinergic esters
Abstract:A method of treating hyperhidrosis in a mammalian subject comprising: and
Inventor(s):Nicholas S. Bodor, David Angulo
Assignee: Bodor Laboratories Inc
Application Number:US14/213,242
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent landscape, scope, and claims:

US Patent 9,220,707: Scope, Claims, Expiration, Orange Book Status, and Sofpironium Patent Landscape

US Patent 9,220,707 covers topical treatment and dosing of hyperhidrosis with specific quaternary ammonium anticholinergic compounds, principally sofpironium bromide. The claims require a defined chemical structure, 1% to 25% concentration, bedtime application, at least 25% sweat reduction for six hours, efficacy comparable to topical glycopyrrolate, and an improved safety profile. The patent was granted on December 29, 2015, and has a nominal expiration date in March 2033, subject to any applicable patent-term adjustment or terminal disclaimer.

The patent is commercially relevant to Sofdra, the sofpironium bromide topical gel approved by the FDA in 2024 for primary axillary hyperhidrosis in patients aged nine years and older. The strongest practical protection is concentrated in the active-ingredient genus, stereochemical variants, concentration range, bedtime dosing, and comparative safety and efficacy limitations.

What drug and technology does US Patent 9,220,707 protect?

The patent protects topical use of pyrrolidinium bromide compounds related to glycopyrrolate but structurally modified with an alkoxycarbonylmethyl substituent.

The principal commercial compound is sofpironium bromide, also known as BB-4000 or BB-4010 in development materials. Its chemical name is generally represented as:

3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(methoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

The claimed compounds have:

  • A cyclopentyl-phenyl-hydroxyacetoxy moiety;
  • A pyrrolidinium core;
  • A methyl or ethyl alkoxycarbonylmethyl substituent;
  • Defined stereochemistry at the 2 position;
  • R, S, or racemic configurations at the 1' and 3' positions;
  • Bromide as the counterion.

The patent is therefore broader than a claim limited to a single commercial stereoisomer or a single formulation. It reaches specified stereochemical mixtures and both methyl and ethyl variants.

What are the independent claims in US 9,220,707?

Claims 1 and 9 are the two independent claims.

Claim Claim type Core requirements
1 Method of treating hyperhidrosis Topical administration of 1% to 25% of the claimed compound before bedtime
9 Method of dosing a hyperhidrosis subject Substantially similar dosing method, framed as a dosing method rather than treatment

Both independent claims require:

  1. A pharmaceutically acceptable vehicle.
  2. A compound within the defined pyrrolidinium bromide genus.
  3. Topical administration to affected skin.
  4. Administration before bedtime.
  5. At least 25% reduction in sweat production.
  6. Duration of at least six hours.
  7. Sweat reduction substantially equivalent to topical glycopyrrolate.
  8. An improved safety profile compared with topical glycopyrrolate.

The duplication of claims 1 and 9 creates two infringement theories. Claim 1 is directed to treatment. Claim 9 is directed to dosing. In practice, both claims would likely be asserted against a product or regimen using the claimed compound for hyperhidrosis.

How broad is the chemical scope of the patent?

The chemical scope is materially broader than sofpironium bromide alone.

Claim 1 covers compounds in which:

  • R is methyl or ethyl;
  • The compound has the required R configuration at the 2 position;
  • The 1' and 3' positions may have R, S, or RS configurations, or mixtures;
  • The concentration is approximately 1% to 25%.

Claim 7 lists 16 named compounds or stereochemical variants. Claims 15 and 16 repeat the same compound coverage under the dosing-method branch.

This structure creates several layers of protection:

Protection layer Scope
Chemical genus Methyl and ethyl alkoxycarbonylmethyl derivatives
Stereochemistry Individual stereoisomers and mixtures
Composition 1% to 25% concentration
Formulation Solutions, gels, creams, lotions, foams, suspensions, emulsions and other vehicles
Administration Topical application to hyperhidrotic skin
Timing Before bedtime
Outcome At least 25% sweat reduction for at least six hours
Comparator Substantially equivalent efficacy to topical glycopyrrolate
Safety Improved safety profile relative to topical glycopyrrolate

A product using the same active ingredient but a different dosage form could still fall within the claims because the formulation language is expansive.

What formulations are protected by US Patent 9,220,707?

The dependent claims cover nearly every conventional topical dosage form.

Claimed formulations include:

  • Solid or semisolid preparations;
  • Powders;
  • Gels;
  • Creams;
  • Lotions;
  • Foams;
  • Solutions;
  • Suspensions;
  • Emulsions.

The claims specifically identify compositions containing approximately 2% to 10% of the compound and a 5% solution in 70% ethanol. Claims 25 through 36 extend the solvent coverage to:

  • Ethanol alone;
  • Isopropyl alcohol alone;
  • Ethanol or isopropyl alcohol with water as a cosolvent.

The formulation coverage is therefore not limited to the commercial Sofdra gel. A competing product could face exposure even if it uses an alcohol solution, cream, foam, or lotion rather than a gel.

Does the patent cover Sofdra?

The claims appear directed to the active ingredient and treatment regimen used for Sofdra.

Sofdra is a 12.45% topical gel containing sofpironium bromide and is indicated for primary axillary hyperhidrosis. The commercial product is administered topically, generally once daily in the evening, consistent with the claimed bedtime regimen. The FDA approved Sofdra on June 18, 2024, under NDA 214697 for patients nine years of age and older.[2]

The commercial concentration is above the 1% minimum and within the broad 1% to 25% range in claims 1 and 9. It is also within the 2% to 10% range only if concentration is expressed on a different active-equivalent or formulation basis. The commercial formulation should therefore be evaluated against the precise concentration convention used in the patent and product labeling.

When does US Patent 9,220,707 expire?

The patent was granted on December 29, 2015. Its nominal term is generally calculated from the earliest effective nonprovisional or PCT filing date, not from the grant date. Based on the reported March 15, 2013 filing date, the nominal expiration date is March 15, 2033, before any patent-term adjustment.[1]

Event Date
Earliest reported priority March 16, 2012
US/PCT filing March 15, 2013
US publication January 2, 2014
Patent grant December 29, 2015
Nominal expiration March 15, 2033

The provisional priority date generally does not determine the 20-year patent term. A final freedom-to-operate analysis should use the USPTO patent-term calculation, including any patent-term adjustment and terminal disclaimer information.

What is the Orange Book status of US 9,220,707?

US Patent 9,220,707 is relevant to the approved Sofdra product and has been treated in public drug-patent materials as a core patent for sofpironium bromide hyperhidrosis treatment. FDA Orange Book treatment depends on the patent’s listing against the specific NDA and dosage form. Method-of-use patents can be listed when they claim an approved use.

The commercial significance of an Orange Book listing is substantial:

  • An ANDA applicant may submit a Paragraph IV certification;
  • The NDA holder can bring patent litigation within the statutory window;
  • A timely suit can trigger an automatic 30-month stay of approval, subject to statutory exceptions;
  • A generic applicant may attempt a section viii statement if it seeks approval without the patented use, although that strategy is difficult when the approved product is principally used for the claimed indication.

The Orange Book listing should be distinguished from the patent’s underlying validity. Listing is an FDA regulatory act and does not establish that the patent would survive an invalidity or infringement challenge.

What Paragraph IV challenges and generic entry risks exist?

The provided record does not identify a filed Paragraph IV challenge or a completed generic litigation proceeding involving US 9,220,707. The patent’s remaining term creates a substantial barrier to a conventional generic launch before 2033 unless a challenger succeeds in litigation, obtains a settlement permitting earlier entry, or uses a noninfringing regulatory strategy.

A generic applicant would likely assess the following vulnerabilities:

Comparative-result limitations

The claims require efficacy substantially equivalent to topical glycopyrrolate and an improved safety profile. These limitations may create proof issues because infringement would require comparative clinical or pharmacological evidence.

The same limitations can also create validity questions. A challenger could argue that the terms "substantially equivalent" and "improved safety profile" lack objective boundaries or are insufficiently supported across the full claimed chemical and formulation scope.

Bedtime administration

A product label that directs administration at another time could create a noninfringement position. That defense would depend on actual use, labeling language, induced infringement evidence, and whether patients routinely administer the product before bedtime.

Concentration and active-ingredient identity

A formulation outside the 1% to 25% concentration range, or a compound outside the claimed stereochemical and structural genus, could avoid literal infringement. The doctrine of equivalents could still be relevant, particularly for close stereochemical or ester substitutions.

Indication carve-outs

A generic seeking treatment of a different sweating condition might attempt to avoid the patented hyperhidrosis use. That strategy would be commercially limited if most foreseeable use remained the patented indication.

How strong is the patent estate for sofpironium?

US 9,220,707 is strong at the regimen level but less secure at the functional-limitation level.

Issue Assessment
Active-ingredient coverage Strong for listed sofpironium-related compounds
Stereochemical coverage Broad, including mixtures and multiple configurations
Formulation coverage Broad
Bedtime dosing Narrower, but commercially aligned with Sofdra use
Hyperhidrosis indication Directly aligned with the approved product
Comparative efficacy limitation Potential infringement-proof issue
Improved-safety limitation Potential construction and proof issue
Design-around potential Moderate for timing, chemistry, concentration, or use
Generic entry before expiration High litigation and stay risk
Post-expiration competition Significant risk from generic or alternative anticholinergic products

The patent’s commercial strength comes from the combination of chemical and method limitations. A competitor would need to avoid more than one limitation to reduce risk.

What patent litigation affects sofpironium and hyperhidrosis products?

The principal competitive products are:

Product Active ingredient Manufacturer or sponsor Delivery Regulatory status
Sofdra Sofpironium bromide Brickell Biotech Topical gel FDA approved in 2024
Qbrexza Glycopyrronium tosylate Journey Medical / Dermira legacy program Topical cloth FDA approved
Drysol and related products Aluminum chloride Multiple manufacturers Topical solution Established products
Botox OnabotulinumtoxinA AbbVie Injection Approved for selected hyperhidrosis use
Oral anticholinergics Oxybutynin and others Multiple manufacturers Oral tablet Off-label or jurisdiction-dependent

No specific completed Paragraph IV settlement or final infringement judgment is established by the supplied claim record. Licensing and patent ownership should be separated from litigation status.

What licensing deals affect the patent landscape?

Sofpironium was developed through a relationship involving Kaken Pharmaceutical and Brickell Biotech. Kaken developed the compound in Japan, where sofpironium bromide was approved as Ecclock for primary axillary hyperhidrosis. Brickell obtained rights to develop and commercialize the product in specified territories, including the United States.[3]

The commercial license matters because patent enforcement may involve:

  • Patent ownership by the original inventor or licensor;
  • Exclusive development rights held by the commercial sponsor;
  • Royalty or milestone obligations;
  • Rights to prosecute continuations and enforce patents;
  • Territory-specific patent families.

The licensing arrangement does not itself expand the scope of US 9,220,707. It affects who controls enforcement and commercialization.

How does US 9,220,707 compare with glycopyrrolate patents?

US 9,220,707 is not a conventional glycopyrrolate patent. It uses glycopyrrolate as a comparator and claims structurally related anticholinergic compounds.

Issue US 9,220,707 Glycopyrrolate product patents
Primary active Sofpironium-related pyrrolidinium compound Glycopyrrolate or glycopyrronium
Claimed use Topical hyperhidrosis treatment and dosing Product-specific topical or systemic uses
Comparator Topical glycopyrrolate Usually not required
Key differentiator Improved safety profile and bedtime dosing Formulation, delivery system, or use
Main commercial product Sofdra Qbrexza and other glycopyrronium products
Design-around path Chemistry, timing, concentration, indication Alternative formulation or delivery

This distinction matters because a competitor may avoid US 9,220,707 by using glycopyrronium itself, but that product may face separate Orange Book patents covering Qbrexza or another glycopyrronium formulation.

What manufacturing and IP barriers exist?

The patent does not claim a manufacturing process in the provided claims. Its main barrier is use of the compound in a covered topical regimen, not synthesis.

Manufacturing risks may still arise from:

  • Access to pharmaceutical-grade sofpironium bromide;
  • Control of stereochemical composition;
  • Impurity profiles;
  • Salt and polymorph selection;
  • Stability in hydroalcoholic or aqueous vehicles;
  • Scale-up of the topical gel;
  • Bioequivalence and local tolerability testing.

A manufacturer could avoid process infringement under this patent while still facing method-of-use exposure when its product is marketed for hyperhidrosis.

What generic launch scenarios are most likely?

Three launch scenarios are commercially relevant.

Early negotiated entry

A generic applicant could challenge the patent and settle for an agreed launch date before March 2033. The settlement could include restrictions based on product labeling, formulation, or indication.

Litigation-driven entry

A Paragraph IV filing could lead to patent litigation and a 30-month stay. Early launch would depend on invalidity, noninfringement, or a court ruling that the Orange Book listing does not block approval.

Post-expiration entry

Absent a successful challenge or settlement, broad generic entry is most likely after the patent term ends. A generic could then compete through a gel, solution, cream, foam, or other topical formulation, subject to FDA requirements for the applicable abbreviated pathway.

Key Takeaways

  • US 9,220,707 covers topical hyperhidrosis treatment with sofpironium-related pyrrolidinium bromide compounds.
  • Claims 1 and 9 are the core independent claims and cover both treatment and dosing methods.
  • The claimed concentration range is approximately 1% to 25%.
  • The claims require bedtime dosing, at least six hours of sweat reduction, glycopyrrolate-comparable efficacy, and improved safety.
  • Claims 7 and 15 cover 16 chemical and stereochemical variants.
  • Formulation claims reach gels, solutions, creams, lotions, foams, suspensions, emulsions, powders and semisolids.
  • The patent was granted December 29, 2015, with a nominal expiration in March 2033 before any patent-term adjustment.
  • The patent is directly relevant to Sofdra, FDA-approved in 2024 for primary axillary hyperhidrosis.
  • The most significant legal vulnerabilities are the comparative efficacy, "substantially equivalent," and "improved safety profile" limitations.
  • No completed Paragraph IV litigation or settlement is established by the supplied claim record.
  • A competing product would face the greatest risk if it uses sofpironium bromide, a covered concentration, topical administration, bedtime dosing and the hyperhidrosis indication.

FAQs

Is US Patent 9,220,707 a composition patent?

No. The supplied claims are method claims. They protect using specified compounds in topical hyperhidrosis treatment and dosing, rather than claiming the compound composition in the abstract.

Does the patent cover oral sofpironium bromide?

No. The claims require topical administration to skin affected by hyperhidrosis. Oral administration would not satisfy the express topical-use limitation.

Does a 12.45% sofpironium product fall within the patent?

It falls within the broad 1% to 25% concentration range, subject to the precise active-ingredient, formulation, bedtime, efficacy and safety limitations of the claims.

Can a competitor avoid the patent by using a cream instead of a gel?

Not necessarily. The claims expressly include creams and multiple other topical dosage forms. Changing the dosage form alone may not avoid infringement.

Does FDA approval prove that the patent is valid?

No. FDA approval and Orange Book listing are regulatory events. Patent validity remains subject to judicial review, including anticipation, obviousness, written description, enablement, indefiniteness and other defenses.

References

  1. United States Patent and Trademark Office. (2015). U.S. Patent No. 9,220,707: Methods of treating hyperhidrosis.
  2. U.S. Food and Drug Administration. (2024, June 18). FDA approves new treatment for primary axillary hyperhidrosis.
  3. Kaken Pharmaceutical Co., Ltd. (2020). Ecclock gel 2%: Japanese prescribing and product information.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,220,707

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Botanix Sb SOFDRA sofpironium bromide GEL, METERED;TOPICAL 217347-001 Jun 18, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,220,707

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014227923 ⤷  Start Trial
Brazil 112015023153 ⤷  Start Trial
Canada 2904724 ⤷  Start Trial
China 105050596 ⤷  Start Trial
China 109364066 ⤷  Start Trial
Denmark 2968267 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.